E Fund Management Co. Ltd. Trims Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

E Fund Management Co. Ltd. cut its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 20.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,465 shares of the biopharmaceutical company’s stock after selling 5,361 shares during the period. E Fund Management Co. Ltd.’s holdings in TG Therapeutics were worth $364,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Pingora Partners LLC acquired a new stake in shares of TG Therapeutics during the fourth quarter valued at about $27,000. Ashton Thomas Private Wealth LLC acquired a new stake in shares of TG Therapeutics during the second quarter valued at about $35,000. DekaBank Deutsche Girozentrale acquired a new stake in shares of TG Therapeutics during the first quarter valued at about $58,000. Lazard Asset Management LLC acquired a new stake in shares of TG Therapeutics during the first quarter valued at about $91,000. Finally, nVerses Capital LLC increased its position in shares of TG Therapeutics by 34.9% during the second quarter. nVerses Capital LLC now owns 5,800 shares of the biopharmaceutical company’s stock valued at $103,000 after acquiring an additional 1,500 shares during the last quarter. 58.58% of the stock is currently owned by institutional investors and hedge funds.

TG Therapeutics Trading Up 0.7 %

Shares of TGTX stock opened at $25.25 on Thursday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.83 and a current ratio of 3.58. The stock has a market capitalization of $3.90 billion, a P/E ratio of 109.78 and a beta of 2.21. The company has a 50 day moving average price of $21.84 and a 200 day moving average price of $18.20. TG Therapeutics, Inc. has a fifty-two week low of $6.46 and a fifty-two week high of $26.41.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.08. TG Therapeutics had a net margin of 27.60% and a return on equity of 57.73%. The firm had revenue of $73.47 million during the quarter, compared to analysts’ expectations of $65.92 million. During the same quarter in the previous year, the business posted ($0.34) earnings per share. The business’s quarterly revenue was up 357.0% compared to the same quarter last year. Equities research analysts predict that TG Therapeutics, Inc. will post 0.13 EPS for the current fiscal year.

Wall Street Analyst Weigh In

TGTX has been the subject of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and set a $49.00 price target on shares of TG Therapeutics in a research report on Wednesday. The Goldman Sachs Group lifted their price target on shares of TG Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a research report on Wednesday, August 7th. Finally, B. Riley lifted their price target on shares of TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, TG Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $31.83.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.